8-K: INmune Bio Secures $18.9 Million in Registered Direct Offering to Fund Clinical Programs

INmune Bio Inc., a clinical-stage biotechnology company, has successfully closed a registered direct offering, raising approximately $18.9 million in gross proceeds through the sale of 3 million common shares at $6.30 per share, intended for working capital and general corporate purposes.

Summary

• INmune Bio Inc. completed a registered direct offering, selling 3,000,000 shares of common stock at a purchase price of $6.30 per share.
• The offering generated approximately $18.9 million in gross proceeds for the company.
• A.G.P./Alliance Global Partners acted as the sole placement agent for the offering, receiving a cash fee equal to 7.0% of the gross proceeds.
• Net proceeds from the offering are intended for working capital purposes and general corporate procedures.
• The offering was priced at-the-market under Nasdaq rules.
• The company's executive officers and directors entered into lock-up agreements for a period of fifteen days after the closing date.
• The company acknowledged possessing material non-public top-line data from its Phase 2 MINDFuL trial in early Alzheimer's Disease, with a conference call scheduled for June 30, 2025, to present these results.

Sentiment

Score: 7

Explanation: The successful completion of an $18.9 million registered direct offering, priced at-the-market and attracting healthcare-focused institutional investors, provides crucial funding for INmune Bio's ongoing clinical programs and general corporate purposes. While it entails shareholder dilution, securing capital is a vital positive for a clinical-stage biotechnology company, enabling continued progress in its pipeline.

Positives

• Successfully raised approximately $18.9 million in gross proceeds, providing crucial capital for ongoing operations and clinical development.
• The offering was priced at-the-market under Nasdaq rules, indicating market acceptance of the share price.
• Secured funding from two healthcare-focused institutional investors, suggesting confidence from specialized investors in the company's prospects.

Negatives

• The issuance of 3,000,000 new shares of common stock will result in dilution for existing shareholders.
• A 7.0% placement agent fee, along with reimbursement for certain legal and other expenses, reduces the net proceeds available to the company.

Risks

• Clinical trials for product candidates are in early stages, and there is no assurance that any specific outcome will be achieved.
• Uncertainty exists regarding the company's ability to produce more drug for clinical trials.
• The company's continued operations, research and development, clinical studies, and future product commercialization are dependent on the availability of substantial additional funding.
• Product candidates, including CORDstrom, XPro1595 (XPro), and INKmune, have not been approved by the US Food and Drug Administration (FDA) or any regulatory body, and there is no assurance they will be approved or achieve specific results.
• The company possesses material non-public information, specifically top-line data from the Phase 2 MINDFuL trial in early Alzheimer's Disease, which could adversely impact the price of the securities.

Future Outlook

The company intends to use the net proceeds from the offering for working capital purposes and general corporate procedures. Clinical trials for product candidates are in early stages, and there is no assurance of specific outcomes or regulatory approvals. The company acknowledges the need for substantial additional funding for ongoing operations, research and development, clinical studies, and future product commercialization.

Management Comments

• The Company intends to use the net proceeds from the Offering for working capital purposes and general corporate procedures.

Industry Context

This capital raise by INmune Bio Inc., a clinical-stage biotechnology company, is a common occurrence in the biotech industry, where significant capital is required to fund extensive research and development, particularly for advancing drug candidates through various phases of clinical trials. The use of proceeds for 'working capital and general corporate purposes' is standard for companies at this stage, indicating a need to sustain operations and progress their pipeline without specifying immediate large-scale expenditures. The focus on innate immune system targeting and specific diseases like Alzheimer's and cancer aligns with current trends in precision medicine and immunology research.

Comparison to Industry Standards

• The registered direct offering is a common method for publicly traded biotechnology companies to raise capital efficiently, especially when they have an effective shelf registration statement (Form S-3) in place.
• The pricing 'at-the-market' under Nasdaq rules is typical for such offerings, reflecting current market conditions and avoiding significant discounts that might signal distress.
• A 7.0% placement agent fee is within the customary range for registered direct offerings of this size in the biotechnology sector, which can vary based on deal size, market conditions, and the complexity of the raise.
• The 15-day lock-up period for executive officers and directors is a relatively short duration, but common for registered direct offerings, aiming to provide some stability post-offering without imposing long-term restrictions on insiders.
• The company's pipeline, including DN-TNF, NK Cell Priming, and hucMSCs platforms, positions it within competitive therapeutic areas such as neurodegenerative diseases (Alzheimer's), oncology, and rare diseases (epidermolysis bullosa), similar to other clinical-stage biotech firms that require continuous funding to de-risk their assets.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of 3,000,000 new shares, but the capital raise provides essential funding for the company's operations and clinical programs, which could potentially increase long-term shareholder value if successful.
• New investors, specifically two healthcare-focused institutional investors, acquired shares at $6.30 per share, gaining exposure to INmune Bio's clinical-stage pipeline.
• Employees may benefit from increased job security and continued progress on clinical programs due to the secured funding.
• Future customers and patients could benefit from the continued development of potential treatments for diseases such as Alzheimer's, cancer, and epidermolysis bullosa, enabled by this funding.

Next Steps

• Use net proceeds for working capital and general corporate purposes.
• Host a conference call on June 30, 2025, to present top-line data from the Phase 2 MINDFuL trial in early Alzheimer's Disease.
• Maintain listing or quotation of common stock on the Trading Market.
• Apply to list or quote all newly issued shares on the Trading Market.
• Continue to use commercially reasonable efforts to maintain eligibility of common stock for electronic transfer through the Depository Trust Company.

Key Dates

Recommendation

Keywords

INmune Bio, INMB, Registered Direct Offering, Equity Raise, Biotechnology, Clinical-stage, Inflammation, Immunology, Alzheimer's Disease, Cancer, Recessive Dystrophic Epidermolysis Bullosa, XPro1595, INKmune, CORDStrom, SEC Filing, Capital Raise, Common Stock, Nasdaq